Physician profile
Clara Lucila Alvarez Villalba
NPI 1497802839
$3,448.23
in general payments reported to CMS, 2019-2025
20 companies · $26.10 in 2025
The $26.10 reported for 2025 was less than what a typical Psychosomatic Medicine provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $463 · 2021: $1,080 · 2022: $280 · 2023: $449 · 2024: $62.81 · 2025: $26.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $666.79 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $571.32 | 2019-2023 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $413.97 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Mycite |
| Abbvie INC. | $374.01 | 2021-2022 | |
| Almatica Pharma LLC | $261.08 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $216.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $189.80 | 2019-2023 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.84 | 2021-2022 | |
| Lundbeck LLC | $112.27 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $108.95 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $108.00 | 2021-2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $45.74 | 2021 | |
| Alkermes, INC. | $36.23 | 2021 | |
| Axsome Therapeutics, INC. | $26.10 | 2025 | Auvelity |
| Janssen Biotech, INC. | $25.06 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.66 | 2021 | |
| Biogen, INC. | $23.27 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.04 | 2023 | Quviviq |
| Neuronetics, INC. | $22.20 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Alvarez Villalba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.